Nectar Lifesciences Limited announced that its board of directors, in a meeting held on March 02, 2026, approved the infusion of an amount up to ₹120 crores as an inter-corporate loan to its proposed wholly owned subsidiary, Avensis Exports Private Limited, subsequent to the completion of acquisition. The company stated that detailed disclosures regarding the loan agreement, as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, will be intimated to the stock exchanges in due course after the definitive loan agreement is finalized with the proposed wholly owned subsidiary. This disclosure is considered a part of Annexure A of the company's letter dated March 02, 2026. Nectar Lifesciences also clarified that the delay in providing these details was due to an administrative oversight and was inadvertent and unintentional, for which the company expressed regret and assured future adherence to prescribed timelines for furnishing material information. The board meeting commenced at 04:00 P.M. IST and concluded at 04:30 P.M. IST on March 02, 2026.
